Moderna, Inc. (NASDAQ:MRNA) Position Boosted by Quantbot Technologies LP

Quantbot Technologies LP lifted its stake in Moderna, Inc. (NASDAQ:MRNA) by 315.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,307 shares of the company’s stock after purchasing an additional 7,066 shares during the quarter. Quantbot Technologies LP’s holdings in Moderna were worth $387,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the stock. Allworth Financial LP increased its stake in Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock valued at $73,000 after buying an additional 281 shares during the period. Howard Capital Management Inc. raised its holdings in shares of Moderna by 3.1% during the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock worth $416,000 after acquiring an additional 297 shares in the last quarter. Larson Financial Group LLC boosted its position in Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after purchasing an additional 317 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in Moderna by 0.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company’s stock valued at $3,099,000 after purchasing an additional 345 shares in the last quarter. Finally, New Insight Wealth Advisors increased its position in Moderna by 4.4% in the 4th quarter. New Insight Wealth Advisors now owns 8,545 shares of the company’s stock worth $355,000 after purchasing an additional 358 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Price Performance

NASDAQ MRNA opened at $31.12 on Friday. The company’s fifty day moving average is $34.72 and its two-hundred day moving average is $44.62. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47. The firm has a market capitalization of $12.03 billion, a price-to-earnings ratio of -3.35 and a beta of 1.86.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Evercore ISI set a $50.00 price target on Moderna in a report on Friday, February 14th. Bank of America decreased their target price on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. Berenberg Bank raised their price target on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. Citigroup assumed coverage on shares of Moderna in a report on Thursday, March 13th. They issued a “neutral” rating and a $40.00 price objective for the company. Finally, The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and cut their target price for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $59.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.